The Serum Institute of India, which is manufacturing the Oxford University's Covishield vaccine and will hold the phase 3 clinical trials in India from next week, has been issued a showcause notice by the country's drug controller DGCI. Trials for the vaccine were stopped in four nations as a precautionary measure after one of the recipients in the UK showed some adverse symptoms, which are yet to be linked to the vaccine.